Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Multiple Myeloma

    US Partner

    An Introduction to Multiple Myeloma

    Despite numerous advances in the last decade, multiple myeloma remains an incurable disease, characterised by relapses that ultimately result in uncontrolled disease and death. However, novel agents, such as proteasome inhibitors, immunomodulatory drugs and CD38-directed monoclonal antibodies, have substantially improved survival and tolerability. These emerging agents include immune checkpoint inhibitors and chimeric antigen receptor-engineered T-cell therapies, although eventual relapse remains an issue.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Multiple Myeloma Content

    Haematological Malignancies, Multiple Myeloma
    Watch Time: 55 mins
    touchCONGRESS
    Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
    CE/CME ACCREDITED Prof. María-Victoria Mateos, Dr Rakesh Popat, Prof. Evangelos Terpos Translations available:

    Three experts discuss data presented at COMy and EHA 2024 on BCMA-targeting agents in multiple myeloma.

    Learning objectives
    Learning Objectives
    • Evaluate the latest evidence for current BCMA-targeting therapies for patients with multiple myeloma
    • Review emerging BCMA-targeting therapies being evaluated in clinical trials for patients with multiple myeloma
    • Discuss the impact of the latest data for current and emerging BCMA-targeting agents on the future management of patients with multiple myeloma
    touchMEETING HIGHLIGHTS
    The role of anti-CD38-based quadruplet therapy in newly-diagnosed multiple myeloma (NDMM)
    For HCPs in: France, Germany, Italy, and Spain
    View Time: 85 mins Sponsored content

    Highlights from a sponsored symposium at the European Hematology Association (EHA) 2023 Congress exploring quadruplet therapy in NDMM

     

    MAT-GLB-2302932
    Date of Preparation: April 2024
    Multiple Myeloma, Haematological Malignancies
    Watch Time: 32 mins.
    touchEXPERT OPINIONS
    The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials
    CE/CME ACCREDITED Prof. Cristina Gasparetto, Prof. Sagar Lonial, Prof. Sundar Jagannath Translations available:

    Learn about investigational protein degradation and immunomodulatory therapies in multiple myeloma.

    Learning objectives
    Learning Objectives
    • Recognize the unmet needs in patients with relapsed/refractory multiple myeloma
    • Outline the rationale for therapies based on protein degradation and immunomodulation for the treatment of patients with relapsed/refractory multiple myeloma
    • Evaluate the latest evidence for therapies based on protein degradation and immunomodulation for relapsed/refractory multiple myeloma and arrange for appropriate patients to be referred to available clinical trials
    touchMEETING HIGHLIGHTS
    Controversies and consensus around 1q21+ in multiple myeloma
    For HCPs in: France, Germany, Italy and Spain
    View Time: 70 mins Sponsored content

    Three leading experts in multiple myeloma review the latest guidance and clinical implications of 1q21+.

     

    MAT-GLB-2302932 V1.0
    Date of Preparation: January 2024
    Haematological Malignancies, Multiple Myeloma
    Developed by Touch
    PERSEUS trial results: Daratumumab + VRd in newly diagnosed multiple myeloma: ASH 2023, Pieter Sonneveld
    Watch Time: 9 mins

    The randomized phase III PERSEUS trial (NCT03710603) investigated daratumumab in combination with bortezomib, lenalidomide, and dexamethasone (VRd) compared with VRd and lenalidomide alone in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM). Daratumumab, a CD38 monoclonal antibody, is currently approved for use in several treatment regimens aimed at both transplant-eligible and non-transplant-eligible NDMM. In this […]

    Multiple Myeloma
    Developed by Touch
    Binod Dhakal, ASCO 2023: The CARTITUDE-4 trial, ciltacabtagene autoleucel for patients with lenalidomide-refractory multiple myeloma
    Watch Time: 11 mins

    Lenalidomide is a standard of care in multiple myeloma. But with the prevalence of the lenalidomide-refractory population increasing, the CARTITUDE-4 trial aimed to assess ciltacabtagene autoleucel for this patient population. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to discuss the mechanism of action of ciltacabtagene […]

    Multiple Myeloma
    Developed by Touch
    Binod Dhakal, ASCO 2023: The treatment paradigm for multiple myeloma
    Watch Time: 7 mins

    The treatment paradigm for patients with multiple myeloma is very complex. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to break down the treatment paradigm in multiple myeloma, discussing how to handle different patient cases. The abstract entitled ‘First phase 3 results from CARTITUDE-4: Cilta-cel versus […]

    touchEXPERT BRIEFING
    The evolving treatment landscape in relapsed/refractory multiple myeloma
    View Time: 22 mins

    Watch leading experts Shaji Kumar and Rahma Warsame discuss the current and evolving treatment landscape in relapsed/refractory multiple myeloma, as well as key factors influencing treatment decisions.

     

    Date of Preparation: May 2023
    Haematological Malignancies, Multiple Myeloma
    Teclistamab Monotherapy for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma
    Beatrice M Razzo, Alfred L Garfall

    touchREVIEWS in Oncology & Haematology. 2023;19(1):46–51 DOI: https://doi.org/10.17925/OHR.2023.19.1.46

    Multiple myeloma (MM) is the second most common haematological malignancy, with upwards of 35,000 diagnoses in the USA each year.1,2 It remains a leading cause of blood cancer–related mortality worldwide, and although therapeutic advances have allowed for significant improvements in the median overall survival,3,4 the majority of patients still experience cycles of relapse that are eventually fatal.5 While patients with MM are living longer, a subgroup with high-risk disease at diagnosis still does poorly, with a median […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup